A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study

安慰剂 医学 置信区间 随机对照试验 偏头痛 临床试验 麻醉 内科学 物理疗法 病理 替代医学
作者
Jeffrey D. Sharon,Roseanne Krauter,Ricky Chae,Adam Gardi,Maxwell Hum,Isabel Elaine Allen,Morris Levin
出处
期刊:Headache [Wiley]
卷期号:64 (10): 1264-1272 被引量:32
标识
DOI:10.1111/head.14835
摘要

OBJECTIVE: To study if galcanezumab is effective for vestibular migraine (VM). BACKGROUND: There are currently no placebo-controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene-related peptide-targeted monoclonal antibody for VM. METHODS: This was a single site, prospective, double-blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18-75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre-filled syringe, 240 mg the first month, and 120 mg for the second and third months. RESULTS: Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM-PATHI score was reduced 5.1 points (95% confidence interval [CI] -13.0 to 2.7) for placebo (N = 21), and 14.8 points (95% CI -23.0 to -6.5) for galcanezumab (N = 17), a difference of -9.6 (95% CI -20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI -15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI -31.9 to -12.1), a difference of -13.7 (95% CI -20.4 to -8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of -5.7 days (95% CI -10.7 to -0.7, p = 0.026). No serious adverse events were observed. CONCLUSIONS: In this pilot study, galcanezumab was effective in treating VM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被科研通管家采纳,获得10
刚刚
小蘑菇的应助被科研通管家采纳,获得10
刚刚
Owen的应助被科研通管家采纳,获得10
刚刚
爆米花的应助被科研通管家采纳,获得10
刚刚
Akim的应助被科研通管家采纳,获得30
刚刚
爆米花的应助被科研通管家采纳,获得10
刚刚
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
慕青的应助被科研通管家采纳,获得10
1秒前
阿银发布了新的文献求助10
1秒前
科目三的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
梦二完成签到,获得积分10
2秒前
2秒前
吴剑锋完成签到 ,获得积分10
3秒前
飞天小叶完成签到 ,获得积分10
3秒前
凶狠的乐巧完成签到,获得积分10
4秒前
4秒前
科研通AI6.3的应助被光年以北采纳,获得10
4秒前
欢呼以柳完成签到,获得积分10
4秒前
汉堡包的应助被培培采纳,获得20
5秒前
5秒前
超帅建完成签到,获得积分10
5秒前
Nicole发布了新的文献求助10
5秒前
Polymer发布了新的文献求助10
5秒前
笨笨妖妖完成签到 ,获得积分10
5秒前
6秒前
6秒前
xiaoyu完成签到,获得积分10
7秒前
阿泽发布了新的文献求助10
7秒前
aPole完成签到 ,获得积分10
7秒前
ELITOmiko完成签到,获得积分10
9秒前
经竺的应助被阿银采纳,获得10
9秒前
武当山大黄狗完成签到,获得积分10
10秒前
11秒前
跳跃的匪完成签到,获得积分10
12秒前
whh完成签到,获得积分10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565